Cargando…

Trametinib response in heavily pretreated high-grade ovarian cancer: One step towards precision medicine

Traditional treatment failure in recurrent ovarian cancer remains a challenge for clinicians. Tumor genetic testing is a promising tool which has been proved able to identify sensitivity profiles in patients affected by cancers. This may be helpful in choosing targeted systemic treatments, aiming to...

Descripción completa

Detalles Bibliográficos
Autores principales: Cappuccio, Serena, Distefano, Maria Grazia, Ghizzoni, Viola, Fagotti, Anna, Scambia, Giovanni
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7042411/
https://www.ncbi.nlm.nih.gov/pubmed/32128357
http://dx.doi.org/10.1016/j.gore.2020.100547
_version_ 1783501305747079168
author Cappuccio, Serena
Distefano, Maria Grazia
Ghizzoni, Viola
Fagotti, Anna
Scambia, Giovanni
author_facet Cappuccio, Serena
Distefano, Maria Grazia
Ghizzoni, Viola
Fagotti, Anna
Scambia, Giovanni
author_sort Cappuccio, Serena
collection PubMed
description Traditional treatment failure in recurrent ovarian cancer remains a challenge for clinicians. Tumor genetic testing is a promising tool which has been proved able to identify sensitivity profiles in patients affected by cancers. This may be helpful in choosing targeted systemic treatments, aiming to overcome histology boundaries and to avoid unnecessary toxicity. We describe the case of a patient affected by recurrent high-grade serous ovarian cancer responsive to MEK-inhibitors, who had undergone multiple lines of therapy. To our knowledge, this is the first reported case of recurrent high-grade ovarian cancer showing remarkable clinical, radiologic and biochemical response to trametinib. This report suggests that trametinib could be effective in high-grade serous ovarian cancer, although most of promising scientific data on this molecule have focused on low-grade ovarian cancer. Molecular profiling has gradually become part of care for patients affected by recurrent ovarian cancer, however further randomized studies are needed to prove its efficacy in everyday clinical practice.
format Online
Article
Text
id pubmed-7042411
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-70424112020-03-03 Trametinib response in heavily pretreated high-grade ovarian cancer: One step towards precision medicine Cappuccio, Serena Distefano, Maria Grazia Ghizzoni, Viola Fagotti, Anna Scambia, Giovanni Gynecol Oncol Rep Case Report Traditional treatment failure in recurrent ovarian cancer remains a challenge for clinicians. Tumor genetic testing is a promising tool which has been proved able to identify sensitivity profiles in patients affected by cancers. This may be helpful in choosing targeted systemic treatments, aiming to overcome histology boundaries and to avoid unnecessary toxicity. We describe the case of a patient affected by recurrent high-grade serous ovarian cancer responsive to MEK-inhibitors, who had undergone multiple lines of therapy. To our knowledge, this is the first reported case of recurrent high-grade ovarian cancer showing remarkable clinical, radiologic and biochemical response to trametinib. This report suggests that trametinib could be effective in high-grade serous ovarian cancer, although most of promising scientific data on this molecule have focused on low-grade ovarian cancer. Molecular profiling has gradually become part of care for patients affected by recurrent ovarian cancer, however further randomized studies are needed to prove its efficacy in everyday clinical practice. Elsevier 2020-02-13 /pmc/articles/PMC7042411/ /pubmed/32128357 http://dx.doi.org/10.1016/j.gore.2020.100547 Text en © 2020 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Case Report
Cappuccio, Serena
Distefano, Maria Grazia
Ghizzoni, Viola
Fagotti, Anna
Scambia, Giovanni
Trametinib response in heavily pretreated high-grade ovarian cancer: One step towards precision medicine
title Trametinib response in heavily pretreated high-grade ovarian cancer: One step towards precision medicine
title_full Trametinib response in heavily pretreated high-grade ovarian cancer: One step towards precision medicine
title_fullStr Trametinib response in heavily pretreated high-grade ovarian cancer: One step towards precision medicine
title_full_unstemmed Trametinib response in heavily pretreated high-grade ovarian cancer: One step towards precision medicine
title_short Trametinib response in heavily pretreated high-grade ovarian cancer: One step towards precision medicine
title_sort trametinib response in heavily pretreated high-grade ovarian cancer: one step towards precision medicine
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7042411/
https://www.ncbi.nlm.nih.gov/pubmed/32128357
http://dx.doi.org/10.1016/j.gore.2020.100547
work_keys_str_mv AT cappuccioserena trametinibresponseinheavilypretreatedhighgradeovariancanceronesteptowardsprecisionmedicine
AT distefanomariagrazia trametinibresponseinheavilypretreatedhighgradeovariancanceronesteptowardsprecisionmedicine
AT ghizzoniviola trametinibresponseinheavilypretreatedhighgradeovariancanceronesteptowardsprecisionmedicine
AT fagottianna trametinibresponseinheavilypretreatedhighgradeovariancanceronesteptowardsprecisionmedicine
AT scambiagiovanni trametinibresponseinheavilypretreatedhighgradeovariancanceronesteptowardsprecisionmedicine